BNP Paribas Financial Markets
TRIL

BNP Paribas Financial Markets’s Trillium Therapeutics Inc. TRIL Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22,485
Closed -$395K – 4313
2021
Q3 		$395K Buy
22,485
+15,519
+223% +$181K ﹤0.01% 2837
2021
Q2 		$67.6K Buy
+6,966
New +$65.6K ﹤0.01% 3157

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

BNP Paribas Financial Markets's TRIL Position: Q4 2021 in Review

BNP Paribas Financial Markets sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 22,485 shares — an estimated $395K sold.

BNP Paribas Financial Markets first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $395K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • BNP Paribas Financial Markets reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 22,485 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $395K.
  • BNP Paribas Financial Markets first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
  • BNP Paribas Financial Markets's Trillium Therapeutics Inc. position peaked at $395K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2021, filed 9 Feb 2022.